非小细胞肺癌生物标志物检测的现状与未来趋势:美国经验
本文综述美国晚期非小细胞肺癌生物标志物检测的现状与未来趋势,指出指南推荐检测的标志物不断增加,检测模式正从单基因检测转向基于二代测序的综合基因组分析,细胞学和小活检标本已证明足以用于此类分子检测,液体活检和细胞学标本上清液等新型非传统标本正逐渐融入检测流程。
要点
- 晚期非小细胞肺癌生物标志物检测是选择合适治疗的关键。
- 检测模式正从单基因检测转向基于二代测序的综合基因组分析。
- 细胞学和小活检标本足以用于分子检测,液体活检等新型标本正融入检测流程。
核心结论
- 晚期非小细胞肺癌生物标志物检测对选择最合适治疗至关重要。
- 指南推荐检测的标志物不断增加,检测模式向综合基因组分析转变。
- 细胞学和小活检标本足以用于分子检测,液体活检等新型标本逐渐融入检测流程。
研究设计与样本
- 本文为综述,聚焦美国非小细胞肺癌生物标志物检测的现状与未来趋势。
主要发现
- 指南推荐的生物标志物数量不断增长,反映从单基因检测向二代测序综合基因组分析的转变。
- 细胞学和小活检标本已证明足以用于辅助分子检测。
- 液体活检和细胞学标本上清液等替代标本在临床领域显示出应用前景。
临床怎么用
- 对晚期非小细胞肺癌患者应进行生物标志物检测以指导治疗选择。
- 可考虑使用细胞学或小活检标本进行分子检测。
- 液体活检和细胞学标本上清液等新型标本可逐步纳入检测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biomarker testing in patients with advanced stage non-small cell lung cancer provides essential information that can be used to select the most appropriate therapy. The regular updates of guideline recommendations reflect the growing number of biomarkers that must be assessed, and as such signal the shift from single-gene assays to more comprehensive genomic profiling using next-generation sequencing modalities. Cytology and small biopsy specimens have proven to be more than adequate substrates for these types of ancillary molecular testing; however, other alternative testing substrates are beginning to emerge. These include so-called liquid biopsies as well the supernatant fluid from cytology specimens, both of which have demonstrated promise for use in the clinical realm. This review will briefly cover the current state of non-small cell lung cancer biomarker testing in the United States, with a focus on these novel nonconventional substrates that are increasingly being incorporated into testing paradigms.
引用
- VanderLaan PA, Roy-Chowdhuri S. Current and future trends in non-small cell lung cancer biomarker testing: The American experience. Cancer Cytopathol. 2020. PMID: 32885913. doi:10.1002/cncy.22313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。